Tuberculosis and Respiratory Diseases

The Korean Academy of Tuberculosis and Respiratory Diseases (대한결핵및호흡기학회)
권호 표지

Acute Respiratory Failure Developed in Non-small Cell Lung Cancer Patients Treated With Gefitinib

비소세포 폐암환자에서 Gefitinib 투여 중 발생한 급성호흡부전

  • Ryu, Jeong-Seon (Department of Internal Medicine, College of Medicine, Inha University) ;
  • Kim, Lucia (Department of Pathology, College of Medicine, Inha University) ;
  • Kim, Chul-Hyun (Department of Internal Medicine, College of Medicine, Inha University) ;
  • Kim, Hyun-Jung (Department of Internal Medicine, College of Medicine, Inha University) ;
  • Cho, Jae-Hwa (Department of Internal Medicine, College of Medicine, Inha University) ;
  • Kwak, Seung-Min (Department of Internal Medicine, College of Medicine, Inha University) ;
  • Lee, Hong-Lyeol (Department of Internal Medicine, College of Medicine, Inha University)
  • 류정선 (인하대학교 의과대학 내과학교실) ;
  • 김루시아 (인하대학교 의과대학 병리학교실) ;
  • 김철현 (인하대학교 의과대학 내과학교실) ;
  • 김현정 (인하대학교 의과대학 내과학교실) ;
  • 조재화 (인하대학교 의과대학 내과학교실) ;
  • 곽승민 (인하대학교 의과대학 내과학교실) ;
  • 이홍렬 (인하대학교 의과대학 내과학교실)
  • Received : 2007.01.15
  • Accepted : 2007.02.02
  • Published : 2007.02.28
Download PDF
⟨ Previous Next ⟩

Abstract

Gefitinib is an oral selective inhibitor that targets the tyrosine kinase of the epidermal growth factor receptor. The prevalence of interstitial lung disease is 2% in Japan and 0.3% in the USA with a mortality rate of up to one third. We describe two non-small cell lung cancer patients who developed acute respiratory failure after gefitinib, and suggest that clinicians take extreme caution when deciding to treat patients with gefitinib.

저자 등은 gefitinib 투약 중 발생한 급성호흡곤란으로 사망한 2 예를 경험하였기에 이를 보고하는 바이다.

Keywords

References

  1. Ando M, Okamoto I, Yamamoto N, Takeda K, Tamura K, Seto T, et al. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2006;24:2549-56 https://doi.org/10.1200/JCO.2005.04.9866
  2. Cohen MH, Williams GA, Sridhara R, Chen G, McGuinn WD Jr, Morse D, et al. United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 2004;10:1212-8 https://doi.org/10.1158/1078-0432.CCR-03-0564
  3. Takano T, Ohe Y, Kusumoto M, Tateishi U, Yamamoto S, Nokihara H, et al. Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib. Lung Cancer 2004;45:93-104 https://doi.org/10.1016/j.lungcan.2004.01.010
  4. Inoue A, Saijo Y, Maemondo M, Gomi K, Tokue Y, Kimura Y, et al. Severe acute interstitial pneumonia and gefitinib. Lancet 2003;361:137-9 https://doi.org/10.1016/S0140-6736(03)12190-3
  5. Seto T, Seki N, Uematsu K, Tanigaki T, Shioya S, Koboyashi T, et al. Gefitinib-induced lung injury successfully treated with high-dose corticosteroids. Respirology 2006;11:113-6 https://doi.org/10.1111/j.1440-1843.2006.00794.x
  6. Ohyanagi F, Ando Y, Nagashima F, Narabayashi M, Sasaki Y. Acute gefitinib-induced pneumonitis. Int J Clin Oncol 2004;9:406-9 https://doi.org/10.1007/s10147-004-0418-0
  7. Rabinowits G, Herchenhorn D, Rabinowits M, Weatge D, Torres W. Fatal pulmonary toxicity in a patient treated with gefitinib for non-small cell lung cancer after previous hemolytic-uremic syndrome due to gemcitabine. Anticancer Drugs 2003;14:665-8 https://doi.org/10.1097/00001813-200309000-00014
  8. Ieki R, Saitoh E, Shibuya M. Acute lung injury as a possible adverse drug reaction related to gefitinib. Eur Respir J 2003;22:179-81 https://doi.org/10.1183/09031936.03.00098503
  9. Okamoto I, Fujii K, Matsumoto M, Terasaki Y, Kihara N, Kohrogi H, et al. Diffuse alveolar damage after ZD1839 therapy in a patient with non-small cell lung cancer. Lung Cancer 2003;40:339-42 https://doi.org/10.1016/S0169-5002(03)00043-6
  10. Inomata S, Takahashi H, Nagata M, Yamada G, Shiratori M, Tanaka H, et al. Acute lung injury as an adverse event of gefitinib. Anticancer Drugs 2004;15:461-7 https://doi.org/10.1097/01.cad.0000127666.12215.7b
  11. Nagaria NC, Cogswell J, Choe JK, Kasimis B. Side effects and good effects from new chemotherapeutic agents: case 1. Gefitinib-induced interstitial fibrosis. J Clin Oncol 2005;23:2423-4 https://doi.org/10.1200/JCO.2005.04.055
  12. Sumpter K, Harper-Wynne C, O'Brien M, Congleton J. Severe acute interstitial pneumonia and gefitinib. Lung Cancer 2004;43:367-8 https://doi.org/10.1016/j.lungcan.2003.09.016
  13. Suzuki H, Aoshiba K, Yokohori N, Nagai A. Epidermal growth factor receptor tyrosine kinase inhibition augments a murine model of pulmonary fibrosis. Cancer Res 2003;63:5054-9
  14. Ishii Y, Fujimoto S, Fukuda T. Gefitinib prevents bleomycin-induced lung fibrosis in mice. Am J Respir Crit Care Med 2006;174:550-6 https://doi.org/10.1164/rccm.200509-1534OC
  15. Fujiwara Y, Kiura K, Toyooka S, Takigawa N, Tokumo M, Hotta K, et al. Relationship between epidermal growth factor receptor gene mutations and the severity of adverse events by gefitinib in patients with advanced non-small cell lung cancer. Lung Cancer 2006;52:99-103 https://doi.org/10.1016/j.lungcan.2005.12.004